Shearman & Sterling advised the underwriters of Inozyme Pharma, Inc.’s follow-on offering of 14,375,000 shares of common stock at a public offering price of $4.80 per share, resulting in net proceeds to the Company of approximately $64.5 million, after deducting underwriting discounts and commissions and estimated offering expenses. The shares sold in the offering included 1,875,000 shares issued pursuant to the underwriters’ option to purchase additional shares.

BofA Securities, TD Cowen and Piper Sandler acted as joint book-running managers for the offering and Wedbush PacGrow and Needham & Company acted as co-managers.

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton.

The Team